⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

November 4, 2015Journal for ImmunoTherapy of CancerOpen Access

Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model

Patricia Rayman C. Marcela Díaz‐Montero Yu‐Shih Yang Brian I. Rini Paul Elson James H. Finke

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Meeting abstracts Combined therapy using the checkpoint blockade anti-PD1 antibody and the TKI, sunitinib, has been investigated in metastatic renal cell carcinoma (mRCC). Here we examined the impact of sunitinib plus anti-PD1 therapy on tumor growth in the renal cell carcinoma mouse model RENCA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rayman et al. (2015) studied this question.

synapsesocial.com/papers/6a5ec63141a6873424592250 https://doi.org/10.1186/2051-1426-3-s2-p310

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1CD39, CD73, and CD38 track tumor burden and reveal immune remodeling during mogamulizumab therapy in Sézary syndromeJournal for ImmunoTherapy of Cancer · 2026
2Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progressionJournal for ImmunoTherapy of Cancer · 2026
3Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell deathJournal for ImmunoTherapy of Cancer · 2026
4Propionate promotes CD8 + T-cell infiltration and enhances immunotherapy efficacy in colorectal cancerJournal for ImmunoTherapy of Cancer · 2026
5PTPN22 as a novel therapeutic target: a key intracellular checkpoint for NK cell therapyJournal for ImmunoTherapy of Cancer · 2026
6Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A)Journal for ImmunoTherapy of Cancer · 2026
7Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort studyJournal for ImmunoTherapy of Cancer · 2026
8Stereotactic body radiation therapy enriches mediators of humoral immune activity in metastatic renal cell carcinomaJournal for ImmunoTherapy of Cancer · 2026
9Affinity-optimized bispecific CAR-T cells targeting HLA-G and CD70 for the treatment of clear cell renal cell carcinomaJournal for ImmunoTherapy of Cancer · 2026
10PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancerJournal for ImmunoTherapy of Cancer · 2026

More from Journal for ImmunoTherapy of Cancer

More from Cleveland Clinic